News Releases
All Releases
View Summary Peregrine Pharmaceuticals Highlights Clinical Data Presentation at AACR 2017 Annual Meeting Supporting Potential of Bavituximab to Enhance Anti-tumor Activity of Immunotherapy
Apr 4, 2017
PDF 56.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Presentation of Preclinical Study Results Highlighting Potential of PS-Targeting Antibodies to Enhance Anti-Tumor Activity of Adoptive T Cell Transfer Therapy with No Added Off-Target Toxicities
Apr 3, 2017
PDF 20.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting
Mar 23, 2017
PDF 57.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments
Mar 13, 2017
PDF 79.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Mar 9, 2017
PDF 15.1 KB Add to Briefcase
View Summary Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 After Market Close on March 13, 2017
Mar 6, 2017
PDF 15.5 KB Add to Briefcase
View Summary Avid Bioservices to Participate at Upcoming Life Sciences Industry Conferences
Feb 22, 2017
PDF 18.3 KB Add to Briefcase
View Summary Recent Publication Highlights Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer
Feb 9, 2017
PDF 18.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent Developments
Dec 12, 2016
PDF 109.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Dec 6, 2016
PDF 14.2 KB Add to Briefcase
View Summary Peregrine to Report Financial Results for Second Quarter of Fiscal Year 2017 After Market Close on December 12, 2016
Dec 5, 2016
PDF 15.4 KB Add to Briefcase
View Summary New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals' PS-Targeting Antibodies in a Preclinical Melanoma Model
Nov 14, 2016
PDF 22.5 KB Add to Briefcase
View Summary Preclinical Research Demonstrates Peregrine Pharmaceuticals' PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC)
Oct 24, 2016
PDF 18.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 Congress
Oct 10, 2016
PDF 94.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer (TNBC)
Sep 27, 2016
PDF 22.1 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress
Sep 21, 2016
PDF 18.9 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent Developments
Sep 8, 2016
PDF 37.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
Sep 6, 2016
PDF 14.6 KB Add to Briefcase
View Summary National Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals' Bavituximab in Multiple Cancers
Sep 6, 2016
PDF 25.8 KB Add to Briefcase
View Summary Peregrine to Report Financial Results for First Quarter of Fiscal Year 2017 After Market Close on September 8, 2016
Sep 1, 2016
PDF 15.3 KB Add to Briefcase
Showing 21-40 of 640 Page: 1 2 3 4 5 6 ... 32  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
Print E-mail